An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
Launched by ABBVIE · Nov 9, 2018
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
Patients with type C hepatitis genotypes 1-6 who had been prescribed Maviret (glecaprevir/pibrentasvir) in accordance with approved local label.
The sample size for this study is due to a requirement by local authorities.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants with chronic C hepatitis genotypes 1 to 6.
- • Participants prescribed Maviret in accordance with approved local label.
- Exclusion Criteria:
- • - Patients with contraindications to the approved local labels for Maviret.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cheonan Si, Chungcheongnamdo, Korea, Republic Of
Anyang, Gyeonggido, Korea, Republic Of
Bucheon, Gyeonggido, Korea, Republic Of
Buncheon, Gyeonggido, Korea, Republic Of
Goyang, Gyeonggido, Korea, Republic Of
Goyang, Gyeonggido, Korea, Republic Of
Seongnam, Gyeonggido, Korea, Republic Of
Suwon, Gyeonggido, Korea, Republic Of
Suwon, Gyeonggido, Korea, Republic Of
Uijeongbu, Gyeonggido, Korea, Republic Of
Yangsan Si, Gyeongsangnamdo, Korea, Republic Of
Iksan, Jeonrabugdo, Korea, Republic Of
Gwangju, Jeonranamdo, Korea, Republic Of
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Busan, , Korea, Republic Of
Busan, , Korea, Republic Of
Busan, , Korea, Republic Of
Busan, , Korea, Republic Of
Busan, , Korea, Republic Of
Busan, , Korea, Republic Of
Busan, , Korea, Republic Of
Busan, , Korea, Republic Of
Changwon, , Korea, Republic Of
Changwon, , Korea, Republic Of
Cheonan, , Korea, Republic Of
Chuncheon, , Korea, Republic Of
Daegu, , Korea, Republic Of
Daegu, , Korea, Republic Of
Daegu, , Korea, Republic Of
Daegu, , Korea, Republic Of
Daegu, , Korea, Republic Of
Daegu, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Daejeon, , Korea, Republic Of
Goyang, , Korea, Republic Of
Gumi Si, , Korea, Republic Of
Gwangju, , Korea, Republic Of
Incheon, , Korea, Republic Of
Incheon, , Korea, Republic Of
Incheon, , Korea, Republic Of
Jeju, , Korea, Republic Of
Jeonnam, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Suncheon, , Korea, Republic Of
Ulsan, , Korea, Republic Of
Wonju, , Korea, Republic Of
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials